To include your compound in the COVID-19 Resource Center, submit it here.
After two years in stealth mode, Obsidian Therapeutics Inc. (Cambridge, Mass.) emerged with a $49.5 million series A round led by GV.
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury